Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $77 from $70 and keeps an Overweight rating on the shares. The firm notes the company reported a solid Q3 print with total revenue of $157M, including $32M from Tryngolza sales. Piper commend this name’s recent commercial execution and continue to like the set-up on shares given near- and intermediate-term portfolio expansion opportunities across wholly owned and partnered assets.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals Faces Investor Risks Amid Market Volatility and Milestone Uncertainties
- Ionis Pharmaceuticals price target raised to $100 from $95 at H.C. Wainwright
- Ionis Pharmaceuticals price target raised to $94 from $90 at Morgan Stanley
- Ionis Pharmaceuticals price target raised to $99 from $59 at TD Cowen
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating